#Israel #AI Technology #Tel Aviv #Mana.bio #lipid nanoparticles

Transforming RNA Delivery: Mana.bio's Breakthroughs

Mana.bio, a pioneering biotechnology firm based in Tel Aviv, has recently showcased remarkable progress in RNA delivery systems by leveraging artificial intelligence (AI) and machine learning (ML). At the 3rd annual LNP Immunogenicity Toxicity Summit held on December 10, 2024, Mana.bio presented compelling data demonstrating how their innovative AI-driven safety model has significantly improved the tolerability of systemic lipid nanoparticles (LNP).

The company commenced its journey with a lung-targeting AI model, resulting in an initial candidate that exhibited highly specific delivery to lung tissues. Within a mere three months, Mana.bio's iterative in-silico and in-vitro cycles allowed them to develop a second-generation LNP candidate that boosted in-vivo potency by an astonishing factor of 100. This leap forward illustrates the effectiveness of AI in predicting and enhancing the properties of therapeutic delivery systems.

Yogev Debbi, co-founder and CEO of Mana.bio, expressed excitement over the rapid pace of innovation, stating, "The speed at which our team was able to generate new data, implement changes, and train new models is phenomenal. This demonstrates our ability to expedite the drug development process by years as compared to traditional development timelines."

Mana.bio’s approach to drug development is multifaceted, integrating extensive data compiled from public databases with real-time empirical data generated in their proprietary laboratory. This curated dataset is then utilized to train machine learning models capable of generating novel lipids and LNP compositions tailored for specific therapeutic applications.

Combining both wet-lab and dry-lab performances, the firm has produced a comprehensive library of high-quality data points derived from thousands of LNP formulations. This innovative methodology has enabled them to identify essential LNP characteristics that optimize both potency and tolerability, vital for systemic administration to extrahepatic targets.

Moreover, the company developed a machine learning model that predicts critical safety metrics for LNPs, covering various aspects from cellular to immunological responses, hematological impacts, and potential hepatotoxicity. The data presented at the summit highlights significant advancements in LNP design that ensures broad improvements in safety while retaining the desired specificity and potency required for effective RNA delivery.

Since securing seed funding in 2023, Mana.bio has demonstrated successful in-vivo delivery mechanisms across various extrahepatic organs. The leadership team of the company is set to share further insights at the upcoming JP Morgan Healthcare Conference scheduled for January 13-16 in San Francisco, California.

To further explore Mana.bio’s groundbreaking work in the realm of RNA therapies and lipid nanoparticles, interested individuals can visit their website at www.mana.bio or reach out via email at [email protected]. The company's commitment to revolutionizing RNA delivery through AI is not just a significant stride in biotechnology; it's an invitation to envision a future where unmet medical needs can be addressed efficiently and effectively.

About Mana.bio

Mana.bio is rewriting the script in targeted RNA delivery systems, utilizing AI-enabled LNP discovery and optimization. This cutting-edge approach accelerates research and enhances the reliability of tissue-specific delivery, unlocking the expansive potential of RNA therapies across a spectrum of medical conditions.